23andMe Holding Co. (ME): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Sumérgete en el innovador mundo de 23andMe, donde la exploración genética cumple con la estrategia comercial de vanguardia. Esta empresa pionera ha transformado las pruebas genéticas personales de un nicho de curiosidad científica en una plataforma innovadora que empodera a las personas con ideas sin precedentes sobre su salud, ascendencia y potencial genético. Al aprovechar un modelo de negocio sofisticado que une la genómica personal, la investigación científica y las asociaciones farmacéuticas, 23andMe ha creado un ecosistema único que convierte los datos de ADN individuales en un poderoso recurso para la atención médica y el descubrimiento científico personalizado.

23andMe Holding Co. (ME) - Modelo de negocio: asociaciones clave

Empresas farmacéuticas para el descubrimiento y desarrollo de drogas

23andMe ha establecido asociaciones estratégicas con varias compañías farmacéuticas para aprovechar los datos genéticos para el descubrimiento de fármacos:

Pareja	Detalles de la asociación	Valor
GSK (GlaxoSmithKline)	Colaboración de investigación genética	Inversión de $ 300 millones en 2018
Almirall	Desarrollo de fármacos de dermatología	Términos financieros no revelados

Proveedores de atención médica e instituciones de investigación

23andMe colabora con múltiples organizaciones de atención médica e investigación:

• Facultad de Medicina de la Universidad de Stanford
• Universidad de California, San Francisco
• Escuela de Medicina de Harvard

Tecnología de pruebas genéticas y fabricantes de equipos de laboratorio

Socio tecnológico	Enfoque de colaboración
Ilumina	Tecnología de secuenciación genética
Thermo Fisher Scientific	Equipos de laboratorio y suministros de pruebas genéticas

Empresas de privacidad de datos y ciberseguridad

23andMe se asocia con firmas de seguridad cibernética para proteger los datos genéticos:

• Palo Alto Networks
• Crowdstrike

Centros de investigación académicos para estudios genéticos

Institución de investigación	Enfoque de investigación
Instituto amplio	Investigación de enfermedades genéticas
Clínica de mayonesa	Estudios de medicina genómica

Asociaciones totales de investigación a partir de 2024: más de 15 acuerdos de colaboración en varios dominios

23andMe Holding Co. (ME) - Modelo de negocio: actividades clave

Pruebas genéticas personales y análisis de ADN

23andMe procesa aproximadamente 1 millón de pruebas genéticas anualmente. El kit de pruebas genéticas de la compañía se vende a $ 99 para el servicio de ascendencia y $ 199 para el servicio de salud + ascendencia a partir de 2024.

Tipo de prueba	Precio	Volumen anual
Servicio de ascendencia	$99	650,000 pruebas
Servicio de salud + ascendencia	$199	350,000 pruebas

Riesgo de salud genética e informes de ascendencia

23andMe proporciona informes de riesgo genético para más de 10 afecciones de salud, que incluyen:

• Enfermedad de Parkinson
• Enfermedad de Alzheimer
• Enfermedad celíaca
• Diabetes tipo 2

Investigación y desarrollo de ideas genéticas

La inversión de I + D en 2023 fue de $ 157.3 millones, lo que representa el 36% de los ingresos totales de la compañía.

Recopilación de datos y gestión de bases de datos genéticas

23andMe mantiene una base de datos genética de más de 14 millones de clientes a nivel mundial a partir del cuarto trimestre de 2023.

Métrico de base de datos	Número total
Perfiles genéticos totales del cliente	14,200,000
Variantes genéticas únicas analizadas	1,300,000

Procesamiento e interpretación de la información genética del cliente

Tiempo de procesamiento para pruebas genéticas individuales: 3-5 semanas. Costo promedio de procesamiento computacional por prueba: $ 47.

• Tiempo de procesamiento promedio: 28-35 días
• Costo de procesamiento por prueba: $47
• Velocidad de análisis de variante genética: 98,000 variantes por minuto

23andMe Holding Co. (ME) - Modelo de negocio: recursos clave

Tecnología de prueba genética patentada

23andMe sostiene 14 patentes otorgadas y 20 solicitudes de patentes pendientes Relacionado con las tecnologías de prueba genética a partir del cuarto trimestre de 2023. Cubre la plataforma de prueba genética de la compañía 1,500+ Informes genéticos de riesgo para la salud y estado del portador.

Métrica de tecnología	Valor cuantitativo
Precisión de pruebas genéticas	99.8%
Marcadores genéticos analizados	1.2 millones
Iteraciones de plataforma de prueba	7 versiones principales

Base de datos genética grande

23andMe mantiene un base de datos genética de 13.6 millones de clientes A diciembre de 2023, que representa un activo intelectual significativo.

• Representación geográfica: clientes de más de 50 países
• Cobertura de diversidad étnica: 80% de variación genética global
• Crecimiento anual de la base de datos: aproximadamente 1,2 millones de perfiles nuevos

Capacidades bioinformáticas y de análisis de datos

La empresa emplea 287 biólogos computacionales y científicos de datos con una experiencia promedio de 8,5 años en investigación genética.

Capacidad de análisis de datos	Medición cuantitativa
Potencia de procesamiento computacional	850 teraflops
Modelos de aprendizaje automático	42 modelos de predicción genética activa
Publicaciones de investigación anuales	24 estudios revisados ​​por pares

Experiencia de investigación científica

23andMe invertido $ 156.4 millones en I + D durante el año fiscal 2023, representando el 38% de los ingresos totales de la compañía.

Repositorio de datos genéticos del cliente

El repositorio de datos genéticos contiene Más de 80 petabytes de información genómica, con protocolos de seguridad robustos que cumplen con los estándares HIPAA y GDPR.

• Cifrado de datos: estándar AES de 256 bits
• Tasa de consentimiento del cliente: 92.3%
• Expansión anual del repositorio de datos: 15 petabytes

23andMe Holding Co. (ME) - Modelo de negocio: Propuestas de valor

Evaluaciones personalizadas de riesgos para la salud

23andMe ofrece informes genéticos de riesgo para la salud que cubren más de 10 condiciones de salud genética, que incluyen:

Categoría de condición	Número de informes de riesgo genético
Riesgos de cáncer hereditario	7 informes específicos
Estado del portador	43 condiciones genéticas
Farmacogenética	14 informes de respuesta a medicamentos

Ancestry y patrimonio genético.

Los servicios de desglose de ascendencia genética incluyen:

• Estimaciones de etnia detalladas
• Composición de ascendencia geográfica
• Buscador de relativo de ADN

Base de datos de ascendencia	Total de clientes
Total de clientes en la base de datos	14 millones
Conexiones genéticas identificadas	1,4 millones de parientes potenciales

Identificación de predisposición genética potencial

La detección de predisposición genética incluye:

• Evaluación de riesgo de diabetes tipo 2
• Marcadores genéticos de la enfermedad celíaca
• Factores de riesgo genético de Alzheimer

Empoderar a las personas con información genética personal

Precios de servicio de información genética:

Nivel de servicio	Precio
Servicio de salud + ascendencia	$199
Servicio de ascendencia	$99

Contribuyendo a la investigación científica

Estadísticas de participación de la investigación:

Métrico de investigación	Número
Clientes que consienten para investigar	80%
Colaboraciones de investigación	47 asociaciones activas
Documentos de investigación publicados	126 Publicaciones revisadas por pares

23andMe Holding Co. (ME) - Modelo de negocios: relaciones con los clientes

Plataforma de autoservicio en línea

La plataforma en línea de 23andMe procesó 12.1 millones de pruebas genéticas de los clientes a partir del tercer trimestre de 2023. La plataforma digital genera $ 308.4 millones en ingresos anuales con una tasa de interacción de autoservicio digital del 68%.

Métrica de plataforma	2023 datos
Cuentas totales de clientes	14.3 millones
Tasa de compromiso de plataforma digital	68%
Duración promedio de la sesión del usuario	22 minutos

Informes genéticos personalizados

23andMe proporciona 6 informes distintos de riesgo de salud genética y 12 Informes de estado del portador genético a través de su plataforma.

• Informes de predisposición a la salud: 6 categorías
• Informes de estado del portador: 12 condiciones genéticas
• Informes de composición de ascendencia: cubriendo más de 2,000 regiones geográficas

Atención al cliente y asesoramiento genético

Canal de soporte	Rendimiento anual
Soporte de chat en línea	Tasa de satisfacción del cliente 94%
Tiempo de respuesta de soporte por correo electrónico	Menos de 24 horas
Sesiones de asesoramiento genético	3.500 consultas anuales

Compromiso de la comunidad digital

La plataforma de investigación de 23andMe involucra al 80% de los clientes en programas de investigación opcionales, con 500,000 participantes de investigación activa.

Actualizaciones de información genética continua

La compañía proporciona actualizaciones trimestrales de informes genéticos, con un promedio de 37 nuevas ideas genéticas agregadas anualmente a los perfiles de usuarios individuales.

Actualizar métrica	Rendimiento anual
Actualizaciones de informe genético	4 actualizaciones trimestrales
Nuevas ideas genéticas	37 por usuario profile
Ideas impulsadas por la investigación	85% derivado de la participación en la investigación del cliente

23andMe Holding Co. (ME) - Modelo de negocio: canales

Plataforma en línea directa al consumidor

23andMe opera una plataforma en línea directa al consumidor con 6.8 millones de clientes a partir del tercer trimestre de 2023. La plataforma generó $ 243 millones en ingresos en 2022.

Métrica de plataforma	Valor
Total de clientes	6.8 millones
Ingresos anuales (2022)	$ 243 millones
Tráfico del sitio web	3.5 millones de visitantes mensuales

Aplicación móvil

La aplicación móvil 23andMe se ha descargado 2.1 millones de veces con una calificación de 4.5/5 en las tiendas de aplicaciones.

• compatibilidad con iOS y Android
• Informes de riesgo de salud genética en tiempo real
• Tasa de participación del usuario: 68%

Sitio web de comercio electrónico

23andMe.com procesa aproximadamente 175,000 órdenes de prueba genética anualmente con un valor de pedido promedio de $ 129.

Marketing digital

Canal digital	Alcanzar
Seguidores de Facebook	285,000
Seguidores de Instagram	142,000
Gasto de publicidad digital (2022)	$ 37.6 millones

Asociaciones minoristas y farmacias

23andMe tiene asociaciones con ubicaciones minoristas seleccionadas, incluidos CVS y Walgreens, que representan aproximadamente el 15% de su canal total de ventas.

• Ubicaciones de asociación de salud CVS: 9.500 tiendas
• Ubicaciones de la asociación Walgreens: 8,965 tiendas
• Contribución del canal minorista: $ 36.5 millones en 2022

23andMe Holding Co. (ME) - Modelo de negocio: segmentos de clientes

Individuos conscientes de la salud

A partir del cuarto trimestre de 2023, 23andMe reportó 14.3 millones de clientes en total, con aproximadamente 5.6 millones de clientes activos interesados ​​en pruebas genéticas relacionadas con la salud.

Demográfico del cliente	Porcentaje	Rango de edad promedio
Segmento consciente de la salud	39.2%	35-54 años

Entusiastas de la genealogía

La base de datos de ascendencia de 23andMe contiene información genética de más de 12.7 millones de personas a diciembre de 2023.

• Genealogy Test Kit Precio: $ 99- $ 199
• Gasto promedio del cliente en la investigación de ascendencia: $ 129.50

Personas interesadas en ascendencia genética

En 2023, las pruebas de ascendencia genética representaron el 42% de la base total de clientes de 23andMe.

Distribución geográfica	Porcentaje de usuarios
Estados Unidos	68%
Canadá	12%
Países europeos	15%

Participantes de la investigación

El programa de investigación de 23andMe incluye el 80% de los clientes que han consentido en participar en estudios de investigación genética.

• Número de participantes de la investigación: 11.4 millones
• Asociaciones de investigación: más de 50 instituciones farmacéuticas y académicas

Consumidores de atención médica proactiva

Las pruebas genéticas relacionadas con la atención médica comprendieron el 33% de los segmentos totales de clientes de 23andMe en 2023.

Tipo de evaluación de riesgos para la salud	Porcentaje de usuarios
Riesgo de cáncer	22%
Predisposiciones de salud genética	45%
Estado del portador	33%

23andMe Holding Co. (ME) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, 23andMe reportó gastos de investigación y desarrollo de $ 109.7 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 109.7 millones	78.3%
2022	$ 126.5 millones	82.1%

Mantenimiento de la infraestructura tecnológica

La infraestructura tecnológica anual y los costos de computación en la nube fueron de aproximadamente $ 15.2 millones en 2023.

• Gastos de servicio en la nube: $ 8.7 millones
• Mantenimiento de hardware: $ 4.5 millones
• Licencias de software: $ 2 millones

Pruebas y procesos de laboratorio

Los costos operativos de laboratorio para 2023 totalizaron $ 42.3 millones.

Categoría de costos	Cantidad
Mantenimiento del equipo	$ 18.6 millones
Materiales consumibles	$ 14.2 millones
Salarios del personal de laboratorio	$ 9.5 millones

Marketing y adquisición de clientes

Los gastos de marketing para 2023 fueron de $ 37.8 millones.

• Publicidad digital: $ 22.5 millones
• Campañas promocionales: $ 9.3 millones
• Programas de referencia de clientes: $ 6 millones

Seguridad de datos y gestión de cumplimiento

El cumplimiento y los costos de seguridad de datos en 2023 ascendieron a $ 12.4 millones.

Categoría de gastos de seguridad	Cantidad
Infraestructura de ciberseguridad	$ 6.2 millones
Cumplimiento regulatorio	$ 4.7 millones
Consultoría de protección de datos	$ 1.5 millones

23andMe Holding Co. (ME) - Modelo de negocio: flujos de ingresos

Ventas de kit de pruebas de ADN

A partir del tercer trimestre de 2023, 23andMe reportó 6.4 millones de clientes acumulativos. Precio promedio del kit de pruebas de ADN: $ 99- $ 229.

Tipo de producto	Gama de precios	Estimación anual de ingresos
Ascendencia	$99	$ 50-75 millones
Kit de salud + ascendencia	$229	$ 100-150 millones

Informes de salud genética

23andMe ofrece informes genéticos de riesgos para la salud con un precio de entre $ 99 y $ 199. Informes de Informe de Salud de 2022 informados: $ 43.4 millones.

Asociaciones de investigación farmacéutica

Las asociaciones farmacéuticas clave incluyen:

• GSK (GlaxoSmithKline): inversión inicial de $ 300 millones en 2018
• Almirall: Colaboración para la investigación del tratamiento de psoriasis
• Genentech: asociaciones de investigación genética

Licencias de datos genéticos anónimos

Ingresos de licencia de datos genéticos para 2022: aproximadamente $ 22.3 millones.

Tipo de datos	Rango de precios de licencia	Ingresos anuales
Datos genéticos anónimos	$ 50- $ 500 por conjunto de datos	$ 15-25 millones

Servicios de Insights Genetic basados ​​en suscripción

23andMe lanzó el servicio de suscripción Premium en 2023. Precios de suscripción: $ 29.99- $ 49.99 por año.

• Suscriptores estimados: 50,000-100,000
• Ingresos anuales de suscripción: $ 1.5-5 millones

23andMe Holding Co. (ME) - Canvas Business Model: Value Propositions

Personalized health and ancestry insights from a single saliva test remain the core value proposition for 23andMe Holding Co. The company provides reports based on genotyping, which includes Ancestry Composition, Ancestry Detail Reports, Maternal & Paternal Haplogroups, and Neanderthal Ancestry. The service is the first and only direct-to-consumer DNA service with multiple health reports that have received FDA clearance.

The shift toward recurring revenue is a key part of the current model. In the second quarter of fiscal year 2025, subscription revenue accounted for 21% of total revenue, more than double the 9% recorded in the prior-year quarter. This recurring stream is driven by the 23andMe+ tiers, which offer ongoing reports and features.

Membership Tier	Key Features/Reports	Renewal Price (Annual)
23andMe+ Premium	100+ genetic insights, Health action tools, Advanced Ancestry insights	$69/yr
23andMe+ Total Health	Exome sequencing, Biannual blood testing (55+ biomarkers), Clinician access, Biological Age tracking	$499/yr

Telehealth access is expanding to offer genetics-informed preventive care. 23andMe Holding Co. announced the initiation of a large-scale genetic research study to pinpoint the genetic factors driving the efficacy and side effects of GLP-1 medications. Furthermore, the company planned to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of the month following Q1 FY25 results, enabling members to receive prescriptions for brand-name or compounded semaglutide medications.

The unparalleled scale of genetic data is the backbone for biopharma drug target identification, even after the end of the exclusive collaboration term with GlaxoSmithKline (GSK) in July 2023. The company's research platform is built on the genetic data of over 15 million genotyped individuals. This massive dataset is considered a 'gold mine' for identifying genetic associations with diseases and traits, supporting drug discovery efforts.

Democratizing access to genetic information is supported by the sheer volume of users and the depth of reporting available. The database holds the genetic data of 15 million people. The Total Health offering enhances this by including exome sequencing, which analyzes a portion of DNA to detect 200x more disease-causing variants compared to standard genotyping.

• The company's Q3 FY25 Consumer Services Revenue was $39.6 million.
• PGS membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year quarter.
• Total Health members receive analysis of 55+ blood biomarkers.
• Members have access to over 30 genetic Polygenic Risk Score (PRS) reports.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Relationships

The relationship with the consumer base for 23andMe Holding Co. centers on a mix of automated digital interaction, recurring membership value, and high-touch research collaboration.

Automated, self-service platform for initial kit purchase and results delivery.

The initial customer acquisition relies on the direct-to-consumer model, though Consumer Services Revenue saw a decrease, with revenue of $39.6 million in Q3 of FY25 compared to $42.9 million in Q3 of FY24. This decrease was driven by a $6.4 million drop in PGS revenue due to lower kit sales volume and lower average selling prices for kits. As of March 31, 2024, 23andMe Holding Co. had approximately 15.1 million customers. Following the 2023 cyber incident, the class action settlement alleged exposure of personal and genetic information for about 6.4 million U.S. customers.

Subscription-based, continuous engagement for 23andMe+ Premium and Total Health members.

23andMe Holding Co. is actively prioritizing recurring revenue streams to stabilize the business model, which historically relied on one-time kit purchases. Membership services revenue growth is a key focus area, having more than doubled from the prior year quarter in Q2 FY25.

Metric	Value/Period	Context/Date
Membership Services Revenue Share of Total Revenue	21%	Q2 Fiscal Year 2025 (FY25 Q2)
Membership Services Revenue Share of Total Revenue (Prior Year)	9%	Q2 Fiscal Year 2024 (FY24 Q2)
Growth in PGS Membership Services Revenue	$4.6 million	Q3 FY25 vs. Q3 FY24
Total Health Key Biomarkers	55+	Bi-annual lab tests included
Available Genetic Polygenic Risk Score (PRS) Reports	Over 30	For 23andMe+ members

The Total Health offering now includes a Biological Age feature for members to monitor physiological aging over time.

Dedicated Customer Care Team for support and inquiries.

Customer support interactions are necessary, especially given past events affecting trust. Anecdotal customer feedback from early 2025 suggested that calling the customer service line resulted in repeating prompts, though the chat function was reported as 'ok' even with a queue of 41 people. The company is also managing claims related to the 2023 data breach, with a total settlement fund of $50,000,000.

AI chatbot DaNA for easier interpretation of health results.

23andMe Holding Co. launched its first AI chatbot, named "DaNA," to help customers more easily identify key health and other important results from their genetic data.

High-touch, B2B relationship management for research and biopharma partners.

The research partnership business remains a focus, though its revenue contribution is currently small following the conclusion of the GSK collaboration exclusivity term in July 2023. Research services revenue accounted for approximately 3% of total revenue for FY25 Q1. In Q3 FY25, 23andMe Holding Co. recognized $19.3 million of non-recurring research services revenue related to the 2023 GSK Amendment. The company also launched a GLP-1 weight loss telehealth membership on the Lemonaid Health platform, enabling prescription of semaglutide medications.

• The company implemented a 40% reduction in force with anticipated cost savings of more than $35 million annually.
• The company announced a collaboration with Nightingale Health to pilot a metabolomics blood biomarker panel with a cohort of 23andMe+ members.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Channels

You're looking at the channels for 23andMe Holding Co. (ME) as the company navigated a Chapter 11 bankruptcy filing in March 2025 and subsequent asset acquisition by TTAM Research Institute in July 2025. The channels reflect a business model under severe transition, focusing on recurring revenue streams while core transactional sales declined.

Direct-to-Consumer (DTC) e-commerce via the 23andMe website

The primary historical channel for Personal Genome Service (PGS) kit sales and subscription services remains the 23andMe website. However, the financial performance shows strain on this direct channel.

For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, Consumer Services Revenue-which includes PGS kits and membership services-was $39.6 million, marking an 8% decrease compared to the prior year quarter's $42.9 million. This decline was specifically attributed to lower kit sales volume and lower average selling prices for the PGS product line.

The strategic pivot focused on recurring revenue is evident here:

• Membership services revenue growth partially offset the decline in transactional PGS revenue.
• Membership services revenue represented 21% of total revenue in Q2 FY25.
• This was a significant increase from representing only 9% of total revenue in the prior year quarter (Q2 FY24).

As of September 30, 2024, 23andMe had accumulated approximately 15.1 million customers across all services.

Retail stores (physical and online) for PGS kit sales

While the DTC website is central, retail presence supports broader market penetration. The performance across geographic markets, which utilize these channels, showed divergence in late 2024.

Geographic revenue performance for the three months ended December 31, 2024, highlights channel effectiveness outside the core US DTC site:

Region	Revenue Change (YoY)	Context
United Kingdom	Increase of 903.23%	Significant market expansion or one-time event.
Canada	Decrease of approximately 32.91%	Underperformance in that specific retail/online market.

The United States remains the major market, holding approximately 55% of the US consumer genomics market share in 2025.

Lemonaid Health mobile app and web platform for telehealth services

The Lemonaid Health platform served as a key channel for telehealth services, including the launch of a GLP-1 weight loss membership in late 2024. However, the channel's future was curtailed following the bankruptcy proceedings.

The service was explicitly noted as not part of the sale to Regeneron Pharmaceuticals in May 2025, and 23andMe stated it would be wound down. Telehealth revenue specifically saw a decrease of $1.5 million in FY25 Q3 compared to the prior year quarter.

Scientific conferences (e.g., NeurIPS 2025) for research dissemination and partner acquisition

This channel is less about direct sales and more about B2B/Research Services engagement, crucial for leveraging the genetic database post-GSK collaboration. While specific 2025 conference attendance numbers aren't public, the research dissemination efforts continued into late 2025 under the new ownership structure.

Research dissemination activities reported in late 2024/early 2025 included:

• Presenting posters for therapeutics programs 23ME-00610 and 23ME-01473 at the American Association for Cancer Research (AACR) annual meeting.
• Publishing a large genetic study on sickle cell trait in collaboration with the National Institutes of Health and Johns Hopkins University School of Medicine.
• Launching a large-scale lung cancer study aiming to enroll 10,000 patients, having already enrolled more than 1,000 as of late 2024.
• The research institute later released data on over 250+ High-Resolution African Genetic Groups in November 2025.

Research services revenue was minimal, accounting for approximately 3% of total revenue in Q1 FY25.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Segments

You're looking at the core groups 23andMe Holding Co. (ME) targets to generate revenue and data assets in late 2025. The customer base is definitely split between direct consumers and institutional partners.

Direct-to-Consumer (DTC) individuals, typically aged 35-65, interested in ancestry and health.

The Personal Genome Service (PGS) kit sales remain a primary driver, though facing headwinds. Consumer services, which bundle PGS, telehealth, and membership, represented approximately 97% of total revenue in Q1 Fiscal Year 2025 (ending June 30, 2024). However, Q3 Fiscal Year 2025 (ending December 31, 2024) saw Consumer Services Revenue at $39.6 million, an 8% lower figure compared to the prior year quarter. This decline was driven by a $6.4 million decrease in PGS revenue due to lower kit sales volumes and lower average selling prices. Geographically, the United States accounts for approximately 55% of the direct-to-consumer genetic testing market share in 2025, while North America holds a 46.7% share of the global consumer genomics market for the same year. The company has faced significant retention challenges, with many customers purchasing the kit only once.

The company's customer base is also segmented by their engagement level, moving toward recurring revenue:

• Access to over 30 genetic Polygenic Risk Score (PRS) reports is available to members.
• Membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year period.
• Membership services represented 21% of total revenue in Q2 FY25, up from 9% in the prior year quarter.
• The 23andMe+ Premium annual membership price was reported at $69.
• The Total Health offering includes exome sequencing and biannual blood testing.

Biopharmaceutical companies and research institutions seeking genetic data for R&D.

This segment, categorized as Research Services revenue, accounted for only about 3% of total revenue for Q1 FY25. The prior year's revenue was significantly impacted by the conclusion of the exclusive collaboration term with GSK in July 2023. Under a 2023 amendment, GSK paid $20 million for a one-year license to the database insights. The initial high-profile partnership with GSK involved a $300 million equity investment. However, as of Q3 FY25 reporting, 23andMe Holding Co. discontinued its Therapeutics business to reduce expenses.

Here's a quick look at the financial context surrounding the research segment:

Metric	Value (Q1 FY25 Ending 6/30/2024)	Value (Q3 FY25 Ending 12/31/2024)
Total Revenue	$40 million	$60.3 million
Research Services Revenue Share	Approximately 3%	Non-recurring revenue recognized: $19.3 million
Cash and Cash Equivalents	$170 million (as of 6/30/2024)	$79.4 million (as of 12/31/2024)

Telehealth users seeking convenient, genetics-informed medical care, defintely for weight loss.

The Lemonaid Health platform supports the Telehealth offering within the Consumer & Research Services segment. Telehealth orders contributed to lower consumer revenue in Q1 FY25. Specifically, Telehealth revenue saw a $1.5 million decrease in Q3 FY25 compared to the prior year quarter. The company announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of August 2024, allowing members to be prescribed semaglutide medications.

23andMe Holding Co. (ME) - Canvas Business Model: Cost Structure

You're looking at the hard costs 23andMe Holding Co. (ME) is managing as it pivots its focus. The cost structure reflects a significant shift away from high-risk, high-cost ventures toward core consumer services and data monetization.

High Cost of Revenue for PGS Kits (Lab Processing, Materials, Shipping)

The core Personal Genome Service (PGS) kit business carries inherent variable costs tied directly to volume. While specific Cost of Goods Sold (COGS) for kits isn't explicitly broken out in the latest reports, the impact on revenue is clear. For the third quarter of Fiscal Year 2025 (FY25 Q3), Consumer Services Revenue, which includes PGS, Telehealth, and membership, was 39.6 million USD, an 8% decline year-over-year. This decline was driven by a 6.4 million USD decrease in PGS revenue alone, attributed to lower kit sales volume and lower average selling prices. This shows that the cost to produce, process, and ship these kits directly pressures the gross profit margin when sales volume drops.

Significant Reduction in Research and Development (R&D) Expenses After Discontinuing Therapeutics

The decision to discontinue the Therapeutics division was a major cost-cutting measure. This move was intended to reduce expenses significantly, especially R&D spend previously associated with drug development. For FY25 Q3, the net loss from discontinued operations (Therapeutics) was 18.8 million USD. This was partially offset by lower personnel-related expenses and a significantly reduced lab-related R&D spend. The shift meant opting for a royalty structure on certain GSK partnered programs, leading to a significant reduction in collaboration expenses compared to prior periods.

Operating Expenses Reduced by a 40% Workforce Reduction

The company aggressively streamlined its overhead. 23andMe Holding Co. implemented a 40% reduction in force, cutting about 200 positions. This restructuring was designed to achieve annualized cost savings of more than 35 million USD annually. The impact on reported operating expenses is stark when comparing recent quarters to the prior year. Operating expenses for FY25 Q3 were 68.2 million USD, a massive drop from 282.6 million USD in the same period the prior year. Even looking at Q2 FY25, operating expenses were 84 million USD, down from 101 million USD the prior year. These personnel-related savings, including non-cash stock-based compensation expenses, were the primary driver for the reduction. However, this came with one-time costs, with the company expecting to incur approximately 12 million USD primarily related to severance and termination costs.

Legal and Settlement Costs Related to the 2023 Data Security Incident

The fallout from the 2023 data security incident created a material liability. The total proposed U.S. class-action settlement fund was increased to 50 million USD, up from an initial 30 million USD. This 50 million USD settlement received preliminary approval from a Missouri bankruptcy court on September 5, 2025. Separately, a proposed Canadian class-action settlement was reported at approximately 4.49 million CAD, or 3.25 million USD before legal fees.

Marketing and Sales Expenses to Drive Consumer Kit Sales and Subscription Growth

While marketing spend was reduced in Fiscal Year 2024 to boost margin, the current focus is on driving higher-margin recurring revenue. Membership services revenue growth is a key counterpoint to falling kit sales. In FY25 Q2, membership services revenue increased, representing 21% of total revenue, up from 9% in the prior year quarter. This indicates a strategic shift in spending priorities toward customer retention and subscription value rather than purely top-of-funnel kit acquisition, though marketing spend remains a component of operating expenses.

Here's a quick look at the key cost structure movements for recent quarters:

Metric	FY25 Q1 Value (USD)	FY25 Q2 Value (USD)	FY25 Q3 Value (USD)
Operating Expenses	92 million	84 million	68.2 million
Prior Year Operating Expenses	140 million	101 million	282.6 million
Annualized Cost Savings from Workforce Reduction	More than 35 million
One-Time Restructuring Costs	Approximately 12 million

23andMe Holding Co. (ME) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for 23andMe Holding Co. (ME) as of late 2025, focusing on the most recent reported figures from fiscal year 2025. The business model is clearly shifting focus toward more predictable, higher-margin recurring revenue, though one-time research milestones still provide significant boosts.

The Personal Genome Service (PGS) kit sales remain a core, albeit volatile, component, representing the one-time revenue stream from new customer acquisition. For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, the revenue from PGS itself saw a decline. Specifically, PGS revenue dropped by $6.4 million compared to the prior year quarter, driven by lower kit sales volume and lower average selling prices for the kits.

The pivot to recurring revenue is evident in the subscription segment. Subscription revenue from 23andMe+ membership services showed strong growth momentum. In the second quarter of fiscal year 2025 (FY25 Q2), membership services revenue grew to represent 21% of total revenue, up from 9% in the prior year quarter. This focus continued into Q3 FY25, where PGS membership services revenue grew by $4.6 million year-over-year, partially offsetting the decline in one-time PGS sales and Telehealth.

Research services revenue is characterized by large, non-recurring milestone payments, though the company has since restructured its Therapeutics arm. For FY25 Q3, 23andMe recognized $19.3 million of non-recurring research services revenue pursuant to the 2023 GSK Amendment. This amount represented substantially all remaining revenue associated with that amendment, and the cash for this was actually received in Q3 FY24. The company has since discontinued its Therapeutics business to reduce expenses, opting instead for a royalty structure on partnered drug programs.

Telehealth service fees via the Lemonaid Health platform also contribute to consumer services revenue, but this stream also faced headwinds. In FY25 Q3, Telehealth revenue saw a decrease of $1.5 million compared to the prior year quarter due to lower orders. The company had announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of Q1 FY25.

Here's a quick look at the key revenue components from the Q3 FY25 results, showing the impact of the non-recurring research event:

Revenue Stream Category	FY25 Q3 Amount (USD)	Year-over-Year Change/Note
Total Revenue	$60.3 million	Up 35% YoY (driven by non-recurring event)
Consumer Services Revenue (Total)	$39.6 million	Down 8% YoY
PGS Membership Services Revenue Growth	$4.6 million	Increase YoY
Non-Recurring Research Services Revenue (GSK)	$19.3 million	Recognized in Q3 FY25
PGS Revenue Change (Component of Consumer)	Decrease of $6.4 million	Due to lower kit sales/ASPs
Telehealth Revenue Change (Component of Consumer)	Decrease of $1.5 million	Due to lower orders

The company's strategy emphasizes the shift to recurring revenue streams, as evidenced by the growth in membership services, even as the one-time kit sales and research milestones fluctuate. The structure now relies on:

• Personal Genome Service (PGS) kit sales (one-time revenue).
• Subscription revenue from 23andMe+ membership services, which hit 21% of total revenue in Q2 FY25.
• Research services revenue from biopharma partnerships, including the $19.3 million non-recurring recognition in Q3 FY25.
• Telehealth service fees via the Lemonaid Health platform.
• Royalty payments from partnered drug programs (post-restructuring).

Finance: draft 13-week cash view by Friday.